{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/hypercalcaemia/diagnosis/assessment/","result":{"pageContext":{"chapter":{"id":"44ef7f17-c907-5252-8027-300e87635dc4","slug":"assessment","fullItemName":"Assessment","depth":2,"htmlHeader":"<!-- begin field 6fd6ebfa-8887-47a3-8600-aa84014f0559 --><h2>How should I assess unexplained hypercalcaemia?</h2><!-- end field 6fd6ebfa-8887-47a3-8600-aa84014f0559 -->","summary":"","htmlStringContent":"<!-- begin item 80a29318-fc29-46a8-870b-aa84014f051d --><!-- begin field 46cde0bb-c2f5-4843-8222-aa84014f0559 --><p><strong>If a person has unexplained <a class=\"topic-reference internal-reference\" href=\"/topics/hypercalcaemia/background-information/definition/\">mild or moderate</a> hypercalcaemia and has no or minimal symptoms, assess the person to determine the <a class=\"topic-reference internal-reference\" href=\"/topics/hypercalcaemia/background-information/causes/\">underlying cause</a>, depending on clinical judgement.</strong></p><ul><li><strong>Ask about:</strong><ul><li>Any <a class=\"topic-reference internal-reference\" href=\"/topics/hypercalcaemia/diagnosis/diagnosis/\">clinical features</a> of hypercalcaemia, their severity and duration.<ul><li>Note: in cases of malignancy-associated hypercalcaemia, it may be difficult to determine if symptoms are due to hypercalcaemia itself or the underlying malignancy.</li></ul></li><li>Any symptoms suggesting underlying malignancy, such as fever, weight loss, night sweats, decreased appetite, cough, general malaise.</li><li>Any known medical conditions or co-morbidities, such as osteoporosis, fragility fractures, renal stones, or malignancy.</li><li>Any past history of radiotherapy to the head and neck.</li><li>Any family history of hypercalaemia (for example due to genetic forms of primary hyperparathyroidism, or familial hypocalciuric hypercalcaemia).</li><li>Any <a class=\"topic-reference internal-reference\" href=\"/topics/hypercalcaemia/background-information/causes/\">drug treatments</a>, supplements, or over-the-counter preparations that may be causative or contributory.</li></ul></li><li><strong>Examine the person:</strong><ul><li>Assess hydration status — people with hypercalcaemia are often dehydrated due to nephrogenic diabetes insipidus due to reduced oral intake resulting from anorexia, nausea and vomiting due to the hypercalaemia itself.</li><li>Assess for cognitive impairment. See the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/delirium/\">Delirium</a> and <a class=\"topic-reference external-reference\" href=\"/topics/dementia/\">Dementia</a> for more information.</li><li>Assess for signs of an underlying cause, including head and neck, respiratory, abdomen, breast, and lymph node examination. Note: parathyroid adenomas or carcinomas are rarely palpable.</li></ul></li><li><strong>Review the duration and pattern of hypercalcaemia:</strong><ul><li>Check for any previous serum calcium concentrations in the medical records to assess the chronicity of hypercalcaemia.<ul><li>In primary hyperparathyroidism, the increase in serum calcium is usually asymptomatic, <a class=\"topic-reference internal-reference\" href=\"/topics/hypercalcaemia/background-information/definition/\">mild</a> and stable, or slowly progressive over years.</li><li>In malignancy-associated hypercalcaemia, there is often rapid-onset, <a class=\"topic-reference internal-reference\" href=\"/topics/hypercalcaemia/background-information/definition/\">severe</a> hypercalcaemia, and associated systemic symptoms.</li></ul></li></ul></li><li><strong>Consider arranging additional investigations to determine the underlying cause,</strong> depending on clinical judgement, and manage appropriately. See the Scenario on <a class=\"topic-reference internal-reference\" href=\"/topics/hypercalcaemia/management/unconfirmed-cause/\">Hypercalcaemia - unconfirmed cause</a> for more information on ongoing management.<ul><li>Full blood count — to diagnose or exclude anaemia of chronic disease or haematologic malignancy. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/haematological-cancers-recognition-referral/\">Haematological cancers - recognition and referral</a> for more information.</li><li>Erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP) — may be increased in malignancy or other inflammatory or granulomatous conditions.</li><li>Estimated glomerular filtration rate (eGFR) and creatinine — to assess hydration status, for acute kidney injury (AKI) and chronic kidney disease (CKD). See the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/acute-kidney-injury/\">Acute kidney injury</a> and <a class=\"topic-reference external-reference\" href=\"/topics/chronic-kidney-disease/\">Chronic kidney disease</a> for more information.</li><li>Serum and urine protein electrophoresis, including testing for urine Bence-Jones protein — to exclude myeloma. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/multiple-myeloma/\">Multiple myeloma</a> for more information.</li><li>Liver function tests — to exclude liver metastases or chronic liver failure; alkaline phosphatase may be increased in primary hyperparathyroidism, Paget's disease with immobilization, myeloma, or bone metastases. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/jaundice-in-adults/\">Jaundice in adults</a> for more information on chronic liver failure.</li><li>Thyroid function tests — to exclude thyrotoxicosis. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/hyperthyroidism/\">Hyperthyroidism</a> for more information.</li><li>Parathyroid hormone (PTH) — typically raised in primary (and tertiary) hyperparathyroidism, and suppressed or undetectable in malignancy-related hypercalcaemia or other non PTH-dependent causes.<ul><li>Arrange for a random PTH sample and check a serum adjusted calcium level at the same time. Primary hyperparathyroidism may be suggested if the result is above the midpoint of the reference range, or below the midpoint of the reference range with a concurrent adjusted serum calcium level of 2.6 mmol/L or above.</li><li>Check with the local biochemistry laboratory regarding PTH testing collection requirements, such as recording the sample collection time, and sample transport arrangements.</li><li>Note: if PTH testing is not available in primary care, refer the person to an endocrinologist unless a non-endocrine underlying cause is suspected, the urgency depending on clinical judgement.</li></ul></li><li>Vitamin D — if vitamin D toxicity is suspected (rare).<ul><li>Note: vitamin D levels may be low in cases of primary hyperparathyroidism, however assessment for vitamin D insufficiency or deficiency is not needed prior to specialist referral.</li></ul></li><li>Serum cortisol (morning sample at 8–9 am) — if Addison's disease is suspected. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/addisons-disease/\">Addison&#39;s disease</a> for more information.</li><li>Early morning urine sample to measure the urinary albumin:creatinine ratio (ACR) — if CKD is suspected. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/chronic-kidney-disease/\">Chronic kidney disease</a> for more information.</li><li>Chest X-ray — to exclude lung cancer or metastases, lymphoma, sarcoidosis, or tuberculosis. See the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/lung-pleural-cancers-recognition-referral/\">Lung and pleural cancers - recognition and referral</a>, <a class=\"topic-reference external-reference\" href=\"/topics/haematological-cancers-recognition-referral/\">Haematological cancers - recognition and referral</a>, and <a class=\"topic-reference external-reference\" href=\"/topics/tuberculosis/\">Tuberculosis</a> for more information.</li></ul></li></ul><!-- end field 46cde0bb-c2f5-4843-8222-aa84014f0559 --><!-- end item 80a29318-fc29-46a8-870b-aa84014f051d -->","topic":{"id":"c0ab4dd9-cccf-54af-a952-765aa048de1d","topicId":"897bf773-43ef-4092-a798-d9eb4cbcb9cc","topicName":"Hypercalcaemia","slug":"hypercalcaemia","lastRevised":"Last revised in August 2019","chapters":[{"id":"dfffab44-62c8-5590-8bad-e41f249a89e7","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"fbfb541d-eae2-5916-af42-b77d9c9ab401","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"3c7aba33-da1a-580a-b896-fb6026eb2ad8","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"61d715de-b85d-534b-8c6f-0cf5f59814c2","slug":"changes","fullItemName":"Changes"},{"id":"48c69505-e62a-5332-a3ad-fd44bb64bd34","slug":"update","fullItemName":"Update"}]},{"id":"0105d032-866a-57c0-8c83-2f54f2b7b491","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"989b5402-77d7-5cd9-86a7-979019eba917","slug":"goals","fullItemName":"Goals"},{"id":"5d8d7c84-01cb-59e9-a02e-489cb32e799e","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"e7c39bf4-b50f-51f7-ad27-49c431acf456","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"1bb69f34-e184-554d-a518-e9d59c4f95de","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"d7060151-5501-51fc-b393-844af2c2ca54","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"7d4d8cad-82f7-5bb5-8c59-b47873b845b2","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"4408b725-f01f-596c-b319-5ef7dd246c3c","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"28f41cc2-0513-5841-9fa6-1a59bb557452","slug":"definition","fullItemName":"Definition"},{"id":"b1dd3a7e-6be5-523b-a2c5-c41f9b364798","slug":"causes","fullItemName":"Causes"},{"id":"048198e1-607a-55c4-9d7d-a63135379c28","slug":"prevalence","fullItemName":"Prevalence"},{"id":"3c5e2134-d0b1-5804-bc33-86db97dfc33b","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"62c64451-7e13-5be6-b868-01f8198a13ac","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"dc0291c2-c628-503e-a7f7-7f3fa1362b62","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"c5771a8e-2f1e-53ad-a2fc-322152fc3a3e","slug":"confirmation","fullItemName":"Confirmation"},{"id":"44ef7f17-c907-5252-8027-300e87635dc4","slug":"assessment","fullItemName":"Assessment"}]},{"id":"d005c3ba-c691-53c3-b23c-1c70928fb05d","fullItemName":"Management","slug":"management","subChapters":[{"id":"c604ea66-1be5-51cc-b014-9af770bbc709","slug":"unconfirmed-cause","fullItemName":"Scenario: Unconfirmed cause"},{"id":"4863d234-7059-57aa-b9cc-a51e3a1f3424","slug":"known-malignancy","fullItemName":"Scenario: Known malignancy"},{"id":"fb65182a-1069-5bbd-9c43-a547a8632cec","slug":"follow-up-in-primary-care","fullItemName":"Scenario: Follow-up in primary care"}]},{"id":"4017390d-3b38-5741-8d16-22624da35f3d","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"2ec3d6b5-1818-5b5f-af66-bd097d709bf2","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"847bb207-2cb8-5e5f-b3e8-ee87440a71cd","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"47a9d106-98da-5683-9641-88d123a8d071","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"a8225b5a-40b4-53e5-9095-0953daa376fa","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"c60f947f-6176-53b3-9484-54b966632a77","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"b6a6af13-45f8-5258-a611-6d8306bbe251","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"f68489fb-5d5f-5342-94a0-3979f632012b","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"62c64451-7e13-5be6-b868-01f8198a13ac","slug":"diagnosis","fullItemName":"Diagnosis"},"subChapters":[{"id":"af5ddab9-ae8e-58c5-874d-7b4a09d660b1","slug":"basis-for-recommendation-c47","fullItemName":"Basis for recommendation","depth":3,"htmlHeader":"<!-- begin field e835a506-a4e2-4457-b50e-aa84014ff81f --><h3>Basis for recommendation</h3><!-- end field e835a506-a4e2-4457-b50e-aa84014ff81f -->","summary":null,"htmlStringContent":"<!-- begin item c47fdc2a-451e-4231-86aa-aa84014ff7f4 --><!-- begin field 39ea37d2-ebff-44ca-b26a-aa84014ff81f --><p>The recommendations on additional investigations are based on the National Institute for Health and Care Excellence (NICE) clinical guideline <em>Hyperparathyroidism (primary): diagnosis, assessment and initial management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">NICE, 2019</a>], the international consensus documents <em>Guidelines for the management of asymptomatic primary hyperparathyroidism: Summary statement from the fourth international workshop</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Bilezikian et al, 2014</a>], <em>Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the fourth international workshop</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Eastell et al, 2014</a>], and <em>The surgical management of asymptomatic primary hyperparathyroidism: proceedings of the fourth international workshop</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Udelsman et al, 2014</a>]; the Society for Endocrinology guideline <em>Emergency management of acute hypercalcaemia in adult patients</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Walsh, 2016</a>], a UK-based prevalence study of hypercalcaemia of malignancy [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Jick, 2015</a>], and expert opinion in review articles on hypercalcaemia [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Meng, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Minisola, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Turner, 2017</a>], on parathyroid disorders [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Pallan et al, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Michels, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Bilezikian, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Insogna, 2018</a>], on hypercalcaemia of malignancy [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Clines, 2011</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Zagzag, 2018</a>], and in a palliative care textbook <em>Symptom management in advanced cancer</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Twycross et al, 2009</a>].</p><h4>Assessing clinical features on history-taking</h4><ul><li>The recommendation to ask about any symptoms suggesting malignancy is based on the fact that an incidental finding of hypercalcaemia may be the first manifestation of undiagnosed malignancy, however most malignancies are clinically evident by the time they cause hypercalcaemia [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Zagzag, 2018</a>].<ul><li>The information that it may be difficult to determine if symptoms are due to hypercalcaemia or underlying malignancy in cases of malignancy-associated hypercalcaemia is based on expert opinion in a prevalence study of hypercalcaemia of malignancy [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Jick, 2015</a>] and in a palliative care textbook [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Twycross et al, 2009</a>].</li></ul></li><li>The recommendation to ask about history of radiotherapy to the head and neck is based on the fact this may be a risk factor for the development of primary hyperparathyroidism, and may affect whether parathyroid surgery is possible as a curative treatment [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Pallan et al, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Michels, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Udelsman et al, 2014</a>].</li><li>The recommendation to ask about family history is based on the fact that up to 10% of all cases of primary hyperparathyroidism in people under 45 years of age have an underlying genetic predisposition [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Turner, 2017</a>].</li></ul><h4>Assessing clinical features on examination</h4><ul><li>The information on the causes of dehydration in people with hypercalcaemia is based on expert opinion in review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Minisola, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Zagzag, 2018</a>].</li><li>The information that parathyroid adenomas or carcinomas are rarely palpable is based on an international consensus document on surgical management [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Udelsman et al, 2014</a>] and expert opinion in a review article [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Pallan et al, 2012</a>].</li></ul><h4>Reviewing the duration and pattern of hypercalcaemia</h4><ul><li>The information on the typical clinical features of primary hyperparathyroidism and malignancy-associated hypercalaemia is based on expert opinion in review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Clines, 2011</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Meng, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Minisola, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Bilezikian, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Zagzag, 2018</a>].</li></ul><h4>Arranging additional investigations</h4><ul><li>The recommendations to arrange additional blood, urine, and X-ray investigations to assess the underlying cause of hypercalcaemia is based on the NICE clinical guideline on primary hyperparathyroidism [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">NICE, 2019</a>], the international consensus document on diagnosis of asymptomatic primary hyperparathyroidism [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Eastell et al, 2014</a>] and expert opinion in review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Pallan et al, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Michels, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Meng, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Minisola, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Turner, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Insogna, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Zagzag, 2018</a>].<ul><li>The recommendations to arrange a random parathyroid hormone (PTH) sample and serum adjusted calcium level at the same time are based on the NICE clinical guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">NICE, 2019</a>].</li><li>The information on the PTH measurements that may suggest a diagnosis of primary hyperparathyroidism is based on the NICE clinical guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">NICE, 2019</a>].</li><li>The recommendation to arrange an endocrinology referral if PTH testing is not available in primary care is pragmatic, based on what CKS considers to be good clinical practice.</li><li>CKS notes that the NICE clinical guideline on primary hyperparathyroidism recommends checking serum vitamin D levels in secondary care rather than primary care, to reduce potential time delays before specialist referral that may occur while the result is awaited and acted on in primary care [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">NICE, 2019</a>]. This CKS topic includes assessing for other underlying causes and complications of hypercalcaemia in primary care, and therefore it has been included as a possible initial investigation, depending on clinical judgement.</li></ul></li></ul><!-- end field 39ea37d2-ebff-44ca-b26a-aa84014ff81f --><!-- end item c47fdc2a-451e-4231-86aa-aa84014ff7f4 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}